{"id":38888,"date":"2023-07-21T22:06:39","date_gmt":"2023-07-22T02:06:39","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/lilly-joins-biogen-as-alzheimers-drugs-finally-emerge\/"},"modified":"2023-07-21T22:06:40","modified_gmt":"2023-07-22T02:06:40","slug":"lilly-joins-biogen-as-alzheimers-drugs-finally-emerge","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=38888","title":{"rendered":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge"},"content":{"rendered":"
\n

After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month,
\n Biogen
\n and Japanese partner
\n Eisai
\n received full approval for Leqembi, which, significantly, Medicare will pay for. Then, this past Monday,
\n Eli Lilly
\n presented results of donanemab that showed it slowed progression of Alzheimer\u2019s. Donanemab may get approval by year end.<\/p>\n

\n

Both drugs use antibodies that attack amyloid plaque found in the brains of Alzheimer\u2019s victims. They are the first shown to slow early-stage cognitive decline. While only a subset of the more than six million Americans with Alzheimer\u2019s will be eligible for treatment, analysts expect sales of Lilly\u2019s donanemab to hit $3.9 billion in 2027. Lilly stock, already lifted by its obesity drugs, trades at 42 times next 12-month earnings.<\/p>\n

There\u2019s no clear winner yet. Analysts say that donanemab appears slightly more effective than Leqembi, but with a slightly riskier side-effect profile. While Leqembi is given intravenously every two weeks over an indefinite time span, donanemab is infused once a month until the plaque is gone.<\/p>\n

Meanwhile, Dublin-based
\n Prothena
\n has an antibody that attacks not amyloid plaque, but so-called tau tangles. Prothena shares leapt in May, when
\n Bristol Myers Squibb
\n paid $55 million to exercise an option to invest in the therapy, which is in early trials. The stock is up nearly 140% in the past 12 months. <\/p>\n

Last Week<\/h4>\n

Markets<\/h2>\n

It was a turnabout week: The
\n Dow Jones Industrial Average
\n won; the
\n Nasdaq Composite
\n lost. The Dow\u2019s winning streak hit 10 days\u2014Friday was a squeaker\u2014the most since September 2017, as recession fears faded and earnings for Dow stalwarts like
\n Johnson & Johnson
\n and banks not named
\n Goldman Sachs
\n shone. At the Nasdaq, things were bumpier, due to
\n Tesla
\n (down 9.7%) and
\n Netflix
\n (off 8.4%). The Nasdaq thudded 2.1% on Thursday, its biggest decline since March 9. Hardly a disaster: The index is up 34% for 2023, and the Dow, 6.3%. The
\n S&P 500
\n falls in between at 18.2%. <\/p>\n

Companies<\/h2>\n

\n Bank of America
\n and
\n Morgan Stanley
\n beat expectations, while Goldman struggled as it cleaned up its consumer effort and GreenSky acquisition in a moribund M&A market.
\n Charles Schwab
\n beat, as deposits rebounded. Netflix added six million subscribers by cracking down on passwords, but missed on revenue. Tesla saw margins shrink on price cuts. J&J beat and raised its guidance. Blackstone assets passed $1 trillion. <\/p>\n

Deals<\/h2>\n

\n Microsoft
\n agreed to a 10-year deal with
\n Sony
\n to win approval for its
\n Activision Blizzard
\n acquisition, and extended the closing to Aug. 29. The FTC paused the merger\u2019s trial, opening the door to a settlement, and published an update of M&A guidelines, laying out its pro-competition policy. Russian President Putin exited the Ukraine grain accord, bombed Odesa, and seized
\n Carlsberg
\n and
\n Danone
\n assets. <\/p>\n

Next Week<\/h4>\n

Tuesday 7\/25<\/h2>\n

Earnings season<\/strong> rolls on, with several tech titans releasing results.
\n Alphabet
\n and Microsoft report on Tuesday.
\n Meta Platforms
\n follows suit on Wednesday. With the Nasdaq 100 already up 41% this year, the bar to impress investors would seem quite high. This past week, shares of both Netflix and Tesla fell more than 8% the day after they announced earnings.<\/p>\n

Wednesday 7\/26<\/h2>\n

The FOMC announces<\/strong> its monetary-policy decision. Wall Street is certain that the central bank will raise the federal-funds rate by a quarter of a percentage point to 5.25%-5.50%, possibly the last rate hike for this cycle.<\/p>\n

Thursday 7\/27<\/h2>\n

The BEA releases<\/strong> its advance estimate for second-quarter gross-domestic-product growth. Economists forecast a seasonally adjusted annual growth rate of 1.4%.<\/p>\n

Friday 7\/28<\/h2>\n

The BEA reports<\/strong> the core personal consumption expenditures price index for June, which is expected to rise 4.2% from a year earlier, four-tenths of a percentage point less than in May.<\/p>\n

Write to <\/strong>Josh Nathan-Kazis at josh.nathan-kazis@barrons.com and Bill Alpert at william.alpert@barrons.com<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai received full approval for Leqembi, which, significantly, Medicare will pay for. Then, this past Monday, Eli Lilly presented results of donanemab that showed it slowed progression of Alzheimer\u2019s. Donanemab may get approval by year […]<\/p>\n","protected":false},"author":1,"featured_media":38889,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"gallery","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-38888","post","type-post","status-publish","format-gallery","has-post-thumbnail","hentry","category-markets","tag-featured","post_format-post-format-gallery"],"yoast_head":"\nLilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge | iFintechWorld<\/title>\n<meta name=\"description\" content=\"After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=38888\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=38888\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-22T02:06:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-22T02:06:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/07\/1689991599_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1279\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=38888#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=38888\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge\",\"datePublished\":\"2023-07-22T02:06:39+00:00\",\"dateModified\":\"2023-07-22T02:06:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=38888\"},\"wordCount\":631,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=38888#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=38888\",\"url\":\"https:\/\/ifintechworld.com\/?p=38888\",\"name\":\"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-07-22T02:06:39+00:00\",\"dateModified\":\"2023-07-22T02:06:40+00:00\",\"description\":\"After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=38888#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=38888\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=38888#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge | iFintechWorld","description":"After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=38888","og_locale":"en_US","og_type":"article","og_title":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge | iFintechWorld","og_description":"After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai","og_url":"https:\/\/ifintechworld.com\/?p=38888","og_site_name":"iFintechWorld","article_published_time":"2023-07-22T02:06:39+00:00","article_modified_time":"2023-07-22T02:06:40+00:00","og_image":[{"width":1279,"height":640,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/07\/1689991599_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=38888#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=38888"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge","datePublished":"2023-07-22T02:06:39+00:00","dateModified":"2023-07-22T02:06:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=38888"},"wordCount":631,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=38888#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=38888","url":"https:\/\/ifintechworld.com\/?p=38888","name":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-07-22T02:06:39+00:00","dateModified":"2023-07-22T02:06:40+00:00","description":"After years of false starts and regulatory stumbles, Alzheimer\u2019s therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=38888#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=38888"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=38888#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Lilly Joins Biogen as Alzheimer\u2019s Drugs Finally Emerge"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/38888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38888"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/38888\/revisions"}],"predecessor-version":[{"id":38890,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/38888\/revisions\/38890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/38889"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}